Dr. Selwyn Spangenthal, MD

Dr. Spangenthal practices at Novant Health Midtown Outpatient Surgery in Charlotte, North Carolina.

Dr. Spangenthal's NPI, 1710975297, was assigned on October 10, 2005. Dr. Spangenthal holds North Carolina license 26374.

Dr. Spangenthal's primary practice is Novant Health Midtown Outpatient Surgery, at 1918 Randolph Rd, Charlotte, NC 28207 in Mecklenburg County. The practice phone is (336) 277-8757.

Dr. Spangenthal's primary practice is Novant Health Midtown Outpatient Surgery in Charlotte, North Carolina. Dr. Spangenthal is also affiliated with Novant Health Presbyterian Medical Center. Dmand AI also links Dr. Spangenthal to 2 more hospitals and 1 physician office, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Spangenthal practices, 4 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Spangenthal's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Spangenthal is licensed in North Carolina.

CMS data shows 824 Medicare services from Dr. Spangenthal across 6 procedure codes in 2024, for 103 Medicare patients. Medicare paid $43,747 for them. Every service was in an office.

CMS counts 103 Medicare patients who saw Dr. Spangenthal in 2024. The largest group is 65 to 74, with 43 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.66, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Spangenthal's median patient age at 72, with 59% women.

In 2024, Dr. Spangenthal wrote 988 Medicare Part D claims for 150 patients. 46% of them were for generic drugs. CMS names the drug for 781 of them, across 19 drugs with 11 or more claims each, at $226,430 in total drug cost. In 2023, CMS named 611 claims across 16 drugs.

Dmand AI links 11 papers to Dr. Spangenthal, published from 2014 to 2020. 2016 was the busiest year, with 3. The most frequent topics are Administration, Inhalation, Double-Blind Method and Pulmonary Disease, Chronic Obstructive. Dr. Spangenthal has published most often in Chronic Obstr Pulm Dis. Dr. Spangenthal's most frequent co-authors are Colin Reisner, MD, Edward M. Kerwin, MD and Gary Thomas Ferguson, MD.

Dmand AI links Dr. Spangenthal to 5 clinical trials, 2 of them phase 3 studies. Conditions studied include Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive and Lung Neoplasms. GlaxoSmithKline sponsors the most, 2. Open Payments lists research payments to Dr. Spangenthal that name 1 trial.

CMS Open Payments shows 702 general payments to Dr. Spangenthal from 39 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 60% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $41,453. It also lists 70 research payments totaling $380,488 from 2016 to 2020, naming 1 clinical trial.